RDY vs MRNA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RDY · Dr. Reddy's Laboratories$14.91 ▲ 2.62%
MRNA · Moderna$254.19 ▲ 5.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RDY +11.1%
- MRNA +926.6%
Head to head
| Metric | RDY | MRNA |
|---|---|---|
| Price | $14.91 | $254.19 |
| Change today | ▲ 2.62% | ▲ 5.27% |
| Market cap | $12.43B | $101.48B |
| Return, 3 months | +22.7% | +325.0% |
| Return, year to date | +6.9% | +762.0% |
| Return, 1 year | +11.6% | +935.8% |
| P/E (TTM) | 42.0 | -31.9 |
| P/B | 3.0 | 15.0 |
| P/E percentile vs own 5y | 98th | 1st |
| Dividend yield | 0.56% | – |
| Revenue growth (YoY, latest qtr) | -1.5% | +4.4% |
| Net profit growth (YoY) | -36.0% | +5.2% |
| Gross margin | 49.5% | 22.8% |
| Operating margin | 9.5% | -150.2% |
| Net margin | 8.5% | -142.6% |
| Return on equity | 7.5% | -39.0% |
| Analyst target vs. price | -3.8% | -50.7% |
| Analyst buy share | 67% | 23% |
| RSI (14) | 78 | 64 |
| 30-day volatility | 26.4% | 101.4% |
| Max drawdown, 1 year | -26.0% | -34.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRNA is the largest of the group by market value.
- MRNA has returned the most over the past year.
- MRNA carries the lowest trailing P/E.
- MRNA is growing revenue fastest.
- RDY keeps the most profit per dollar of sales.
- RDY has been the calmest stock over the last 30 days.